Brief: Fosun Pharmaceutical's Unit Signs Licensing Agreement With FBD Biologics
30/06/2025 12:01
June 30 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS: SAYS UNIT HENLIUS BIOTECH SIGNS LICENSING AGREEMENT WITH FBD BIOLOGICS Source text Further company coverage: 600196.SS (Reporting by Beijing Newsroom) ((Ethan.Wang@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln